Bold headline: Beth Israel Lahey Health chief Kevin Tabb to step down, ending a 15-year era that reshaped the system. But here’s where it gets controversial: is stepping aside the right move as the network hits new heights?
Overview of leadership impact
Under Dr. Kevin Tabb’s stewardship, the health system posted a $100 million operating gain last year—the first year in the black in four years. An employee survey in the prior spring showed a majority of respondents were satisfied with their workplace and would recommend it to others. The network also expanded its primary care footprint, adding dozens of clinicians in the last year, including many who joined from rival Mass General Brigham.
Why now, and what comes next
Tabb explains the timing as a sign of momentum and stability, not a retreat. “As I talk to people, they want to understand, ’If things are so wonderful, why now?’ In my mind the answer is a simple one: It’s because things are good,” he said. “It’s because we have real momentum, it’s because we’re stable financially. We have the partnerships we need, and there is work to do, but they are solidified for the coming years. And because we have really good people that I feel more than comfortable, I feel good, saying, ‘It’s time for the next person.’” By his departure next year, he will have led the system for 15 years, making him the longest-serving CEO in the Massachusetts hospital network’s history.
Next steps for Tabb
Tabb’s post-Tabb plans remain uncertain. He has stated he’s not interested in leading another large health system or hospital network. “I don’t intend to go run another hospital or health system,” he said. “If I wanted to do that, I already run [an institution] that I love, and one that I think that is the best one out there.” Regarding his next chapter, he added, “I genuinely don’t know.”
A distinguished career with global roots
Tabb’s background spans continents and institutions. Born in Berkeley, California, he relocated to Israel at 18, serving in the Israel Defense Forces. He earned undergraduate and medical degrees from Hebrew University, completed an internal medicine residency at Hadassah Hospital in Jerusalem, and previously led Stanford Hospital & Clinics in California before joining Beth Israel Deaconess Medical Center as chief executive in 2011.
Board and political perspective
Ann-Ellen Hornidge, chair of the Beth Israel Lahey Health board, called Tabb’s departure a “huge loss” for the organization and personally. She cited the pandemic years as particularly taxing, noting, “It’s a hard job. And the pandemic, each one of those years was like in dog years.” The system plans a national search for a replacement over the next eight to ten months, with internal candidates expected to be strong as well. Hornidge will co-lead the process with Ron O’Hanley, CEO of State Street Corporation.
Public reflections on leadership
Governor Maura Healey credited Tabb with steadfast crisis leadership—from the Marathon bombing to COVID-19—saying his partnership strengthened health care in the state and expressing gratitude for his service.
A transformed organization, a bold vision for cancer care
When Tabb started, Beth Israel Deaconess Medical Center was a smaller operation centered in downtown Boston with Needham and Milton–Plymouth expansions forthcoming. A landmark 2019 merger with Lahey Health created the Beth Israel Lahey Health system and brought in Lahey Hospital & Medical Center in Burlington. The consolidation, however, faced early hurdles, including a seven-year price cap on reimbursements that set a distinct regulatory constraint not shared by all regional systems.
Pandemic and performance
The combined system weathered the pandemic’s surge and associated supply challenges, with Hornidge recalling Tabb’s focus on clinician safety and resource access. In recent years, the network has continued shifting care to community sites, with 64 percent of care delivered outside its major academic centers and 1.7 million patients served annually. Primary care recruitment surged, adding 60 clinicians in the last year alone and 30 percent growth over four fiscal years.
Scale and scope
Today, Beth Israel Lahey Health comprises 14 hospitals and about 42,000 employees, including more than 4,800 physicians. The system has also pursued high-profile growth initiatives, including a 2023 agreement for Dana-Farber Cancer Institute to build a new cancer hospital in partnership with Beth Israel Deaconess—an arrangement that breaks with Dana-Farber’s historic ties to Brigham and Women’s Hospital and is slated to open around 2031. Staffing the cancer hospital will require substantial expansion of the network’s oncology workforce.
Leadership succession and continuity
While Tabb’s leadership is ending, Hornidge expressed strong confidence that the organization will continue to execute his strategic vision without missing a beat, highlighting the durable strengths of the Dana-Farber partnership and the broader system’s governance. Dana-Farber’s CEO, Dr. Benjamin L. Ebert, praised Tabb’s leadership as pivotal to the collaboration’s success and to advancing regional cancer care.
Broader challenges ahead
Analysts and stakeholders have warned that the path forward includes potential Medicaid reimbursement cuts, shifting payer dynamics, and rising costs for drugs and other essentials. Debates around diversity, equity, and inclusion initiatives, as well as federal budget pressures for research, are likely to shape the environment for the next leader. Tabb himself notes that ongoing issues—reimbursement reform, access to care, and escalating operating costs—will demand sustained attention from the successor over the next 15 years.
Closing thought
As the health system transitions, the question remains provocative: will the next leader maintain the momentum and tackle the enduring complexities of modern health care, or will new pressures alter the trajectory? Share your thoughts on whether you believe stepping down is the right move at this juncture and what you’d expect from a future leader in this evolving landscape.
